Search fresh public links, source activity, and ready-to-use post angles for Jnjf.
Fresh curated links around JNJF are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Linked here is a detailed quantitative analysis of Johnson & Johnson (JNJ). Below are some highlights from the above linked analysis: Company Description: Johnson &amp...
Johnson & Johnson's new drugs may offset declining sales due to patent-protection losses.
Updated on July 8th, 2026 by Nathan Parsh Only the best companies can increase dividends through multiple recessions. The Dividend Kings are a group of stocks that have increased t...
Johnson & Johnson is putting its name on the first phase of New Brunswick’s HELIX development, where a new innovation hub will support early-stage life sciences startups with l...
Johnson & Johnson has stopped development of an eye disease gene therapy after reviewing data from one of its key readouts for 2026.
J&J has more than 28 sources of blockbuster revenue.
Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced, presentation at ESPGHAN 2026 descr...
Bristol Myers Squibb leans on specialty medicines and a discounted valuation, while Johnson & Johnson boasts industry-leading margins and cash flow.
Johnson & Johnson is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a deal that gives it the option to acquire Sail Biomedicines.
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.